BG
CRNX icon

Bellevue Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bellevue Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98M Sell
2,620,000
-660,000
-20% -$24.5M 2.06% 16
2026
Q1 		$119M Buy
3,280,000
+3,275,960
+81,088% +$146M 2.84% 11
2025
Q4 		$188K Buy
+4,040
New +$180K ﹤0.01% 152

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bellevue Group's CRNX Position: Q2 2026 in Review

Bellevue Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 20% in Q2 2026, selling an estimated $24.5M and leaving 2,620,000 shares worth $98M. The position accounts for 2.06% of the portfolio, ranked #16.

Bellevue Group first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $119M in Q1 2026. 227 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Bellevue Group held 2,620,000 shares of Crinetics Pharmaceuticals worth $98M as of Q2 2026.
  • Bellevue Group sold 660,000 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $24.5M.
  • Crinetics Pharmaceuticals made up 2.06% of Bellevue Group's portfolio in Q2 2026, its #16 holding.
  • Bellevue Group first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Bellevue Group's Crinetics Pharmaceuticals position peaked at $119M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.